Therefore, in treating patients with XLH, the dosage of oral phosphate should be adjusted within an appropriate range when using conventional therapy, based on calcium and PTH levels, to avoid progression from secondary hyperparathyroidism to tertiary hyperparathyroidism. The gene discussed is PTH; the disease is secondary hyperparathyroidism.